Sign In
Buy AVNS
Avanos Medical Earnings Calls
| Release date | Nov 05, 2025 |
| EPS estimate | $0.120 |
| EPS actual | $0.220 |
| EPS Surprise | 83.33% |
| Revenue estimate | 164.5M |
| Revenue actual | 177.8M |
| Revenue Surprise | 8.09% |
| Release date | Aug 05, 2025 |
| EPS estimate | $0.180 |
| EPS actual | $0.170 |
| EPS Surprise | -5.56% |
| Revenue estimate | 167.5M |
| Revenue actual | 175M |
| Revenue Surprise | 4.48% |
| Release date | May 06, 2025 |
| EPS estimate | $0.190 |
| EPS actual | $0.260 |
| EPS Surprise | 36.84% |
| Revenue estimate | 168.25M |
| Revenue actual | 167.5M |
| Revenue Surprise | -0.446% |
| Release date | Feb 26, 2025 |
| EPS estimate | $0.400 |
| EPS actual | $0.430 |
| EPS Surprise | 7.50% |
| Revenue estimate | 172.6M |
| Revenue actual | 179.6M |
| Revenue Surprise | 4.06% |
Last 4 Quarters for Avanos Medical
Below you can see how AVNS performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 26, 2025 |
| Price on release | $15.62 |
| EPS estimate | $0.400 |
| EPS actual | $0.430 |
| EPS surprise | 7.50% |
| Date | Price |
|---|---|
| Feb 20, 2025 | $15.48 |
| Feb 21, 2025 | $15.45 |
| Feb 24, 2025 | $15.63 |
| Feb 25, 2025 | $15.56 |
| Feb 26, 2025 | $15.62 |
| Feb 27, 2025 | $15.21 |
| Feb 28, 2025 | $15.05 |
| Mar 03, 2025 | $15.13 |
| Mar 04, 2025 | $15.02 |
| 4 days before | 0.90% |
| 4 days after | -3.84% |
| On release day | -2.62% |
| Change in period | -2.97% |
| Release date | May 06, 2025 |
| Price on release | $12.85 |
| EPS estimate | $0.190 |
| EPS actual | $0.260 |
| EPS surprise | 36.84% |
| Date | Price |
|---|---|
| Apr 30, 2025 | $12.55 |
| May 01, 2025 | $12.33 |
| May 02, 2025 | $12.29 |
| May 05, 2025 | $12.19 |
| May 06, 2025 | $12.85 |
| May 07, 2025 | $12.58 |
| May 08, 2025 | $12.58 |
| May 09, 2025 | $12.65 |
| May 12, 2025 | $13.10 |
| 4 days before | 2.39% |
| 4 days after | 1.95% |
| On release day | -2.10% |
| Change in period | 4.38% |
| Release date | Aug 05, 2025 |
| Price on release | $9.89 |
| EPS estimate | $0.180 |
| EPS actual | $0.170 |
| EPS surprise | -5.56% |
| Date | Price |
|---|---|
| Jul 30, 2025 | $11.67 |
| Jul 31, 2025 | $11.17 |
| Aug 01, 2025 | $10.98 |
| Aug 04, 2025 | $11.25 |
| Aug 05, 2025 | $9.89 |
| Aug 06, 2025 | $10.33 |
| Aug 07, 2025 | $10.74 |
| Aug 08, 2025 | $10.82 |
| Aug 11, 2025 | $10.52 |
| 4 days before | -15.25% |
| 4 days after | 6.37% |
| On release day | 4.45% |
| Change in period | -9.85% |
| Release date | Nov 05, 2025 |
| Price on release | $10.66 |
| EPS estimate | $0.120 |
| EPS actual | $0.220 |
| EPS surprise | 83.33% |
| Date | Price |
|---|---|
| Oct 30, 2025 | $11.14 |
| Oct 31, 2025 | $11.11 |
| Nov 03, 2025 | $11.20 |
| Nov 04, 2025 | $11.30 |
| Nov 05, 2025 | $10.66 |
| Nov 06, 2025 | $11.18 |
| Nov 07, 2025 | $11.23 |
| Nov 10, 2025 | $11.45 |
| Nov 11, 2025 | $11.66 |
| 4 days before | -4.31% |
| 4 days after | 9.38% |
| On release day | 4.88% |
| Change in period | 4.67% |
Avanos Medical Earnings Call Transcript Summary of Q3 2025
Avanos reported a strong Q3 2025 driven by above-market growth in its Specialty Nutrition Systems (SNS) segment and positive momentum in Pain Management and Recovery, notably double-digit growth in radio frequency ablation (RFA). Consolidated net sales were approximately $178 million for the quarter; organic sales for strategic segments were up ~10% year-over-year (FX- and portfolio-adjusted). The company raised and narrowed its 2025 revenue guidance to $690M–$700M and its adjusted EPS guidance to $0.85–$0.95. Avanos completed the divestiture of its hyaluronic acid business and closed the Nexus Medical acquisition (expected to be immediately accretive). Management announced a cost-improvement program aimed at $15M–$20M of run-rate savings by end of 2026 with roughly $10M of one-time charges (mostly in Q4 2025). Tariffs remain an important headwind — management estimates incremental tariff-related manufacturing costs of about $18M and expects tariff impacts to persist into 2026; the company is pursuing mitigation actions and accelerating moves out of China for certain production (neonatal syringes mid-2026), which increases near-term capex. Balance sheet remains healthy with $70M cash, $103M debt, leverage below 1x, and expected FY free cash flow of ~$25M–$30M (inclusive of transformation charges and tariff impacts). Management emphasized continued M&A appetite for synergistic bolt-ons, focus on portfolio optimization, and improved operating discipline.
